Back to Search
Start Over
Long-Term Outcomes and Prognostic Factors of High-Risk Malignant Melanoma Patients after Surgery and Adjuvant High-Dose Interferon Treatment: A Single-Center Experience
- Source :
- Chemotherapy. 60:228-238
- Publication Year :
- 2014
- Publisher :
- S. Karger AG, 2014.
-
Abstract
- Background: Surgical excision constitutes an important part of the treatment of local advanced malignant melanoma. Due to the high recurrence risk, adjuvant high-dose interferon therapy is still the only therapy used in stage IIB and III high-risk melanoma patients. Methods: One hundred two high-risk malignant melanoma patients who received high-dose interferon-α-2b therapy were evaluated retrospectively. The clinicopathological features, survival times, and prognostic factors of the patients were determined. Results: The median disease-free and overall survival times were 25.2 and 60.8 months, respectively. Our findings revealed that male gender, advanced disease stage, lymph node involvement, lymphatic invasion, the presence of ulceration, and a high Clark level were significant negative prognostic factors. Conclusion: In light of the favorable survival results obtained in this study, high-dose interferon treatment as adjuvant therapy for high-risk melanoma is still an efficient treatment and its possible side effects can be prevented by taking the necessary precautions.
- Subjects :
- Adult
Male
Oncology
medicine.medical_specialty
Skin Neoplasms
Time Factors
Lymphovascular invasion
medicine.medical_treatment
Antineoplastic Agents
Single Center
Risk Factors
Interferon
Internal medicine
Drug Discovery
medicine
Adjuvant therapy
Humans
Pharmacology (medical)
Stage (cooking)
Melanoma
Lymph node
Aged
Retrospective Studies
Pharmacology
business.industry
General Medicine
Middle Aged
Prognosis
medicine.disease
Combined Modality Therapy
Surgery
Survival Rate
Treatment Outcome
Infectious Diseases
medicine.anatomical_structure
Chemotherapy, Adjuvant
Female
Interferons
business
Adjuvant
medicine.drug
Subjects
Details
- ISSN :
- 14219794 and 00093157
- Volume :
- 60
- Database :
- OpenAIRE
- Journal :
- Chemotherapy
- Accession number :
- edsair.doi.dedup.....13fd39adc275238520fa6f86e5613111